Tromsø, Norway, 7 February 2019 - Biotec Pharmacon's (OSE: Biotec) subsidiary
ArcticZymes adds its first ligase enzyme, T4 DNA ligase, to its portfolio.
T4 DNA ligase, the most widely used enzyme in the ligase family, works by
joining DNA fragments together. It is used in the development of kits and
products serving the In Vitro Diagnostic (IVD) and molecular research market
segments.

This launch represents the Company's first non-novel enzyme in its expanding
portfolio and fulfils customer requests for such enzymes. The high-quality and
commercial grade ligase is produced under the strict ISO 13485 guidelines. It
fits synergistically in the Company's portfolio and can be used by customers
either in combination with their own enzymes or alongside ArcticZymes novel
enzymes.

ArcticZymes has several other ligase products in development. Numerous
prototypes of novel ligases are currently with leading commercial customers for
early access evaluations. Customer feedback from these evaluations will then
steer the Company's plans to commercialise further ligases in 2019.

Jethro Holter, Managing Director ArcticZymes said:

"The launch of the T4 DNA ligase fits with our strategy to expand our current
portfolio beyond novel enzyme products. Our goal is to continue to leverage our
experience to grow a synergistic portfolio through organic and non-organic
growth initiatives.

"As a trusted component supplier to the industry we are transitioning the
business towards becoming the leading one-stop shop for molecular biology
enzymes."

- ENDS -

For more information, please contact:

Biotec   Pharmacon
Christian Jørgensen, CEODr     Tel: +47 47 79 24 57
Jethro Holter, MD ArcticZymes  Tel: +47 46 85 91 46
                               Email: contact@arcticzymes.com

Instinctif   Partners
Melanie Toyne-Sewell / Dr      Tel: +44 207 457 2020
Christelle Kerouedan /Deborah  Biotecpharmacon@instinctif.com
Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsoe to offer niche and high tech products in
several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans
addressing high unmet healthcare needs, such as chronic wound healing and as an
adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec
Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon's unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About ArcticZymes

ArcticZymes develops, produces and markets novel recombinant enzymes for use in
molecular research, In Vitro Diagnostics (IVD) and therapeutics.

The Company focuses on novel and high-quality enzyme technologies in growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymes.

Some of its enzymes' unique features include heat lability and activity in
challenging environments as well as customised, engineered novel features which
can be integrated to power the technologies of commercial partners.

All ArcticZymes products are ISO certified.

For more information, please visit: www.arcticzymes.com